Lyka Labs Limited (IN:LYKALABS)
:LYKALABS
Top Page
Lyka Labs Limited
(LYKALABS)
Select Model
Select Model
Rating:54Neutral
Price Target:
₹60.00
▼(-36.44% Downside)
Action:ReiteratedDate:03/28/26
The score is held up by decent underlying financial performance driven by revenue growth and improved operating margins, but is materially weighed down by weak cash flow (negative free cash flow) and a very bearish technical setup (price far below key moving averages with negative momentum). Valuation adds additional risk because the extremely negative P/E makes earnings-based valuation unreliable and there is no dividend yield support.
Positive Factors
Revenue Growth
Sustained strong revenue growth indicates expanding product uptake and market penetration. Over a 2-6 month horizon this supports predictable demand, provides operating leverage potential, and creates capacity to reinvest in R&D or capacity, improving long-term competitiveness and scale economics.
Negative Factors
Weak Cash Generation
Persistent low OCF and negative free cash flow constrain the firm's ability to self-fund capex, working capital, or product launches. Over months this limits strategic flexibility, may force external financing, and raises execution risk for growth initiatives despite accounting profits.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained strong revenue growth indicates expanding product uptake and market penetration. Over a 2-6 month horizon this supports predictable demand, provides operating leverage potential, and creates capacity to reinvest in R&D or capacity, improving long-term competitiveness and scale economics.
Read all positive factors
Lyka Labs Limited (LYKALABS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹2.09B
Dividend YieldN/A
Average Volume (3M)3.02K
Price to Earnings (P/E)―
Beta (1Y)1.30
Revenue Growth4.04%
EPS Growth-35.02%
CountryIN
Employees423
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.00
Shares Outstanding35,690,000
10 Day Avg. Volume1,252
30 Day Avg. Volume3,017
Financial Highlights & Ratios
PEG Ratio-0.12
Price to Book (P/B)3.58
Price to Sales (P/S)2.64
P/FCF Ratio-26.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Lyka Labs Limited Business Overview & Revenue Model
Company Description
Lyka Labs Limited, a pharmaceutical company, engages in development, manufacture, and marketing of pharmaceutical formulations and active pharmaceutical ingredients across various therapeutic segments in India. The company manufactures and sells v...
How the Company Makes Money
Lyka Labs Limited makes money primarily by selling pharmaceutical products. Key revenue streams include (1) sales of finished dosage formulations (e.g., tablets, capsules, injectables and other drug forms) to distributors, hospitals, pharmacies, a...
Lyka Labs Limited Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
68
Positive
Cash Flow
60
Neutral
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.38B | 1.41B | 1.05B | 916.90M | 1.84B | 671.07M |
| Gross Profit | 714.24M | 851.35M | 599.41M | 152.84M | 1.30B | 289.23M |
| EBITDA | 140.68M | 201.67M | 167.59M | 128.47M | 1.01B | 201.17M |
| Net Income | 20.55M | 80.12M | -24.89M | -132.12M | 390.00M | -115.55M |
Balance Sheet | ||||||
| Total Assets | 1.68B | 1.76B | 1.57B | 1.52B | 1.86B | 1.90B |
| Cash, Cash Equivalents and Short-Term Investments | 11.89M | 13.63M | 62.91M | 119.39M | 170.59M | 76.30M |
| Total Debt | 316.57M | 391.84M | 586.50M | 751.02M | 1.30B | 1.63B |
| Total Liabilities | 664.32M | 726.24M | 884.59M | 1.06B | 1.72B | 2.15B |
| Stockholders Equity | 1.01B | 1.04B | 681.54M | 454.41M | 133.38M | -257.97M |
Cash Flow | ||||||
| Free Cash Flow | 51.46M | -137.55M | -74.58M | 7.67M | 717.33M | 75.44M |
| Operating Cash Flow | 136.84M | 18.99M | 17.73M | 89.53M | 792.46M | 88.11M |
| Investing Cash Flow | -46.95M | -117.96M | -94.88M | 73.50M | -61.72M | -1.61M |
| Financing Cash Flow | -91.69M | 52.92M | 19.53M | -216.43M | -631.77M | -117.98M |
Lyka Labs Limited Technical Analysis
Negative
94.40
Price Trends
62.10
Negative
70.86
Negative
87.08
Negative
Market Momentum
-1.97
Negative
53.89
Neutral
81.54
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:LYKALABS, the sentiment is Negative. The current price of 94.4 is above the 20-day moving average (MA) of 53.26, above the 50-day MA of 62.10, and above the 200-day MA of 87.08, indicating a neutral trend. The MACD of -1.97 indicates Negative momentum. The RSI at 53.89 is Neutral, neither overbought nor oversold. The STOCH value of 81.54 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:LYKALABS.
Lyka Labs Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | ₹3.24B | 36.55 | ― | ― | 21.55% | 47.80% | |
63 Neutral | ₹3.47B | 19.99 | ― | ― | -5.82% | -59.22% | |
57 Neutral | ₹2.45B | 20.62 | ― | ― | 43.30% | ― | |
54 Neutral | ₹2.09B | -338,564.26 | ― | ― | 4.04% | -35.02% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | ₹2.11B | 10.71 | ― | ― | 18.67% | ― |
* Healthcare Sector Average
IN:LYKALABS
Lyka Labs Limited
58.69
-44.91
-43.35%
IN:BROOKS
Brooks Laboratories Limited
71.49
-60.91
-46.00%
IN:MEDICO
Medico Remedies Ltd.
39.08
-19.66
-33.47%
IN:NURECA
Nureca Ltd.
257.15
43.30
20.25%
IN:ZIMLAB
Zim Laboratories Ltd.
71.30
-15.80
-18.14%
Lyka Labs Limited Corporate Events
Lyka Labs Completes Amalgamation With Lyka Exports, Boosts Authorised Capital
Apr 9, 2026
Lyka Labs Limited has secured final approval for the amalgamation of group entity Lyka Exports Limited, after the National Company Law Tribunal in Ahmedabad sanctioned the merger and the order was filed with the Registrar of Companies. The scheme,...
NCLT Clears Merger of Lyka Exports With Lyka Labs
Mar 17, 2026
Lyka Labs Limited has announced that the National Company Law Tribunal, Ahmedabad Bench, has approved the amalgamation of Lyka Exports Limited with Lyka Labs under sections 230 to 232 of the Companies Act, 2013. The scheme, with an appointed date ...
Lyka Labs Says NCLT Reserves Order on Amalgamation Scheme After FEMA Compliance Filing
Feb 20, 2026
Lyka Labs Limited has updated exchanges on the status of its proposed scheme of amalgamation, noting that the National Company Law Tribunal has examined its filings on compliance with foreign exchange and import-export regulations. The company rep...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.